Long-acting recombinant follicle-stimulating hormone in random-start ovarian stimulation protocols for fertility preservation in women with cancer

Veronica Sarais, Alessio Paffoni, Luca Pagliardini, Francesca Filippi, Fabio Martinelli, Giorgia Mangili, Massimo Candiani, Enrico Papaleo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

INTRODUCTION: The objective of this study was to assess the effectiveness and potential benefits of the use of long-acting recombinant follicle-stimulating hormone (FSH) in a random-start protocol for fertility preservation in women with cancer.

MATERIAL AND METHODS: This is a retrospective before-and-after study performed between February 2013 and December 2015 in women who underwent ovarian hyperstimulation for oocyte cryobanking using a random-start approach. In the first part of the study period, the women were treated with daily recombinant FSH whereas in the second part the stimulation was initiated with long-acting recombinant FSH. The primary aim of the study was to compare the number of oocytes stored in the two study periods. In all, 140 women were ultimately selected.

RESULTS: Compared with daily recombinant FSH, the use of the long-acting compound was associated with a reduced number of injections (12.5 ± 3.5 vs. 16.4 ± 0.3; p < 0.001) and a longer duration of stimulation (11.4 ± 1.9 vs. 10.6 ± 1.9, p = 0.01). Conversely, the number of oocytes collected (13.7 ± 9.5 vs. 11.3 ± 7.0, p = 0.10) as well as those cryopreserved (11.0 ± 8.0 vs. 9.5 ± 5.8, p = 0.21) did not differ.

CONCLUSIONS: The use of long-acting recombinant FSH in random-start protocols for fertility preservation appears to be a valuable option.

Original languageEnglish
Pages (from-to)949-953
Number of pages5
JournalActa Obstetricia et Gynecologica Scandinavica
Volume96
Issue number8
DOIs
Publication statusPublished - Aug 2017

Fingerprint

Fertility Preservation
Ovulation Induction
Follicle Stimulating Hormone
Oocytes
Neoplasms
Injections

Keywords

  • Breast Neoplasms
  • Delayed-Action Preparations
  • Drug Administration Schedule
  • Female
  • Fertility Preservation
  • Follicle Stimulating Hormone
  • Humans
  • Ovarian Neoplasms
  • Ovulation Induction
  • Pregnancy
  • Retrospective Studies
  • Treatment Outcome
  • Journal Article

Cite this

@article{6a5cfe3727c64214927cdc6fc4941ecf,
title = "Long-acting recombinant follicle-stimulating hormone in random-start ovarian stimulation protocols for fertility preservation in women with cancer",
abstract = "INTRODUCTION: The objective of this study was to assess the effectiveness and potential benefits of the use of long-acting recombinant follicle-stimulating hormone (FSH) in a random-start protocol for fertility preservation in women with cancer.MATERIAL AND METHODS: This is a retrospective before-and-after study performed between February 2013 and December 2015 in women who underwent ovarian hyperstimulation for oocyte cryobanking using a random-start approach. In the first part of the study period, the women were treated with daily recombinant FSH whereas in the second part the stimulation was initiated with long-acting recombinant FSH. The primary aim of the study was to compare the number of oocytes stored in the two study periods. In all, 140 women were ultimately selected.RESULTS: Compared with daily recombinant FSH, the use of the long-acting compound was associated with a reduced number of injections (12.5 ± 3.5 vs. 16.4 ± 0.3; p < 0.001) and a longer duration of stimulation (11.4 ± 1.9 vs. 10.6 ± 1.9, p = 0.01). Conversely, the number of oocytes collected (13.7 ± 9.5 vs. 11.3 ± 7.0, p = 0.10) as well as those cryopreserved (11.0 ± 8.0 vs. 9.5 ± 5.8, p = 0.21) did not differ.CONCLUSIONS: The use of long-acting recombinant FSH in random-start protocols for fertility preservation appears to be a valuable option.",
keywords = "Breast Neoplasms, Delayed-Action Preparations, Drug Administration Schedule, Female, Fertility Preservation, Follicle Stimulating Hormone, Humans, Ovarian Neoplasms, Ovulation Induction, Pregnancy, Retrospective Studies, Treatment Outcome, Journal Article",
author = "Veronica Sarais and Alessio Paffoni and Luca Pagliardini and Francesca Filippi and Fabio Martinelli and Giorgia Mangili and Massimo Candiani and Enrico Papaleo",
note = "{\circledC} 2017 Nordic Federation of Societies of Obstetrics and Gynecology.",
year = "2017",
month = "8",
doi = "10.1111/aogs.13146",
language = "English",
volume = "96",
pages = "949--953",
journal = "Acta Obstetricia et Gynecologica Scandinavica",
issn = "0001-6349",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Long-acting recombinant follicle-stimulating hormone in random-start ovarian stimulation protocols for fertility preservation in women with cancer

AU - Sarais, Veronica

AU - Paffoni, Alessio

AU - Pagliardini, Luca

AU - Filippi, Francesca

AU - Martinelli, Fabio

AU - Mangili, Giorgia

AU - Candiani, Massimo

AU - Papaleo, Enrico

N1 - © 2017 Nordic Federation of Societies of Obstetrics and Gynecology.

PY - 2017/8

Y1 - 2017/8

N2 - INTRODUCTION: The objective of this study was to assess the effectiveness and potential benefits of the use of long-acting recombinant follicle-stimulating hormone (FSH) in a random-start protocol for fertility preservation in women with cancer.MATERIAL AND METHODS: This is a retrospective before-and-after study performed between February 2013 and December 2015 in women who underwent ovarian hyperstimulation for oocyte cryobanking using a random-start approach. In the first part of the study period, the women were treated with daily recombinant FSH whereas in the second part the stimulation was initiated with long-acting recombinant FSH. The primary aim of the study was to compare the number of oocytes stored in the two study periods. In all, 140 women were ultimately selected.RESULTS: Compared with daily recombinant FSH, the use of the long-acting compound was associated with a reduced number of injections (12.5 ± 3.5 vs. 16.4 ± 0.3; p < 0.001) and a longer duration of stimulation (11.4 ± 1.9 vs. 10.6 ± 1.9, p = 0.01). Conversely, the number of oocytes collected (13.7 ± 9.5 vs. 11.3 ± 7.0, p = 0.10) as well as those cryopreserved (11.0 ± 8.0 vs. 9.5 ± 5.8, p = 0.21) did not differ.CONCLUSIONS: The use of long-acting recombinant FSH in random-start protocols for fertility preservation appears to be a valuable option.

AB - INTRODUCTION: The objective of this study was to assess the effectiveness and potential benefits of the use of long-acting recombinant follicle-stimulating hormone (FSH) in a random-start protocol for fertility preservation in women with cancer.MATERIAL AND METHODS: This is a retrospective before-and-after study performed between February 2013 and December 2015 in women who underwent ovarian hyperstimulation for oocyte cryobanking using a random-start approach. In the first part of the study period, the women were treated with daily recombinant FSH whereas in the second part the stimulation was initiated with long-acting recombinant FSH. The primary aim of the study was to compare the number of oocytes stored in the two study periods. In all, 140 women were ultimately selected.RESULTS: Compared with daily recombinant FSH, the use of the long-acting compound was associated with a reduced number of injections (12.5 ± 3.5 vs. 16.4 ± 0.3; p < 0.001) and a longer duration of stimulation (11.4 ± 1.9 vs. 10.6 ± 1.9, p = 0.01). Conversely, the number of oocytes collected (13.7 ± 9.5 vs. 11.3 ± 7.0, p = 0.10) as well as those cryopreserved (11.0 ± 8.0 vs. 9.5 ± 5.8, p = 0.21) did not differ.CONCLUSIONS: The use of long-acting recombinant FSH in random-start protocols for fertility preservation appears to be a valuable option.

KW - Breast Neoplasms

KW - Delayed-Action Preparations

KW - Drug Administration Schedule

KW - Female

KW - Fertility Preservation

KW - Follicle Stimulating Hormone

KW - Humans

KW - Ovarian Neoplasms

KW - Ovulation Induction

KW - Pregnancy

KW - Retrospective Studies

KW - Treatment Outcome

KW - Journal Article

U2 - 10.1111/aogs.13146

DO - 10.1111/aogs.13146

M3 - Article

C2 - 28382680

VL - 96

SP - 949

EP - 953

JO - Acta Obstetricia et Gynecologica Scandinavica

JF - Acta Obstetricia et Gynecologica Scandinavica

SN - 0001-6349

IS - 8

ER -